Evotec SE

SWX:EVT Stock Report

Market Cap: CHF 1.0b

Evotec Valuation

Is EVT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EVT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: EVT (CHF4.9) is trading below our estimate of fair value (CHF21.87)

Significantly Below Fair Value: EVT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EVT?

Key metric: As EVT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EVT. This is calculated by dividing EVT's market cap by their current revenue.
What is EVT's PS Ratio?
PS Ratio1.5x
Sales€756.33m
Market Cap€1.12b

Price to Sales Ratio vs Peers

How does EVT's PS Ratio compare to its peers?

The above table shows the PS ratio for EVT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.7x
PPGN PolyPeptide Group
2.5x14.00%CHF 847.9m
SKAN SKAN Group
3.7x13.78%CHF 1.2b
TECN Tecan Group
1.9x6.27%CHF 1.8b
SFZN Siegfried Holding
2.7x7.00%CHF 3.5b
EVT Evotec
1.5x6.85%CHF 1.1b

Price-To-Sales vs Peers: EVT is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (2.7x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does EVT's PS Ratio compare vs other companies in the European Life Sciences Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
EVT 1.5xIndustry Avg. 3.1xNo. of Companies9PS02.85.68.411.214+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: EVT is good value based on its Price-To-Sales Ratio (1.5x) compared to the European Life Sciences industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is EVT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EVT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate EVT's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EVT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 4.90
CHF 7.89
+61.24%
19.14%CHF 9.70CHF 5.60n/a5
Jan ’27CHF 4.90
CHF 7.89
+61.24%
19.14%CHF 9.70CHF 5.60n/a5
Dec ’26n/a
CHF 8.41
0%
21.89%CHF 11.15CHF 5.58n/a6
Nov ’26n/a
CHF 8.76
0%
20.51%CHF 11.13CHF 5.57n/a7
Oct ’26n/a
CHF 8.82
0%
20.50%CHF 11.21CHF 5.60n/a7
Sep ’26n/a
CHF 8.96
0%
22.97%CHF 11.22CHF 5.61n/a6
Aug ’26n/a
CHF 10.20
0%
41.70%CHF 20.40CHF 5.56n/a8
Jul ’26n/a
CHF 10.64
0%
39.11%CHF 20.67CHF 6.58n/a8
Jun ’26n/a
CHF 10.66
0%
38.86%CHF 20.55CHF 6.54n/a8
May ’26n/a
CHF 11.12
0%
37.99%CHF 20.73CHF 6.60n/a7
Apr ’26n/a
CHF 11.34
0%
46.38%CHF 21.05CHF 3.83n/a6
Mar ’26n/a
CHF 11.10
0%
46.38%CHF 20.60CHF 3.75n/a6
Feb ’26n/a
CHF 10.46
0%
48.41%CHF 20.67CHF 3.76n/a7
Jan ’26n/a
CHF 10.28
0%
45.71%CHF 20.50CHF 3.73CHF 4.908
Dec ’25n/a
CHF 10.32
0%
45.71%CHF 20.57CHF 3.74n/a8
Nov ’25n/a
CHF 9.96
0%
48.74%CHF 20.58CHF 3.74n/a8
Oct ’25n/a
CHF 12.82
0%
52.67%CHF 28.19CHF 3.76n/a10
Sep ’25n/a
CHF 12.82
0%
52.67%CHF 28.19CHF 3.76n/a10
Aug ’25CHF 27.76
CHF 18.48
-33.44%
57.90%CHF 47.96CHF 9.59n/a11
Jul ’25CHF 27.76
CHF 20.63
-25.68%
55.43%CHF 49.62CHF 10.32n/a10
Jun ’25CHF 27.76
CHF 20.63
-25.68%
55.43%CHF 49.62CHF 10.32n/a10
May ’25CHF 27.76
CHF 23.66
-14.78%
45.39%CHF 48.88CHF 10.17n/a10
Apr ’25CHF 27.76
CHF 25.25
-9.03%
37.91%CHF 48.75CHF 13.65n/a10
Mar ’25CHF 27.76
CHF 22.65
-18.40%
26.24%CHF 28.71CHF 13.40n/a9
Feb ’25CHF 27.76
CHF 23.33
-15.95%
22.11%CHF 28.14CHF 14.44n/a8
Jan ’25CHF 27.76
CHF 28.08
+1.14%
28.77%CHF 47.30CHF 17.60n/a9
CHF 6.59
Fair Value
25.7% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/07 07:36
End of Day Share Price 2026/01/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evotec SE is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioBerenberg
Michael RyskinBofA Global Research
Peter VerdultCitigroup Inc